DE602007006985D1 - Mikroorganismen als träger von für antigene und proteintoxine codierende nukleotidsequenzen, verfahren zur herstellung und verwendungen davon - Google Patents

Mikroorganismen als träger von für antigene und proteintoxine codierende nukleotidsequenzen, verfahren zur herstellung und verwendungen davon

Info

Publication number
DE602007006985D1
DE602007006985D1 DE602007006985T DE602007006985T DE602007006985D1 DE 602007006985 D1 DE602007006985 D1 DE 602007006985D1 DE 602007006985 T DE602007006985 T DE 602007006985T DE 602007006985 T DE602007006985 T DE 602007006985T DE 602007006985 D1 DE602007006985 D1 DE 602007006985D1
Authority
DE
Germany
Prior art keywords
proteintoxines
antigene
microorganisms
coding
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007006985T
Other languages
English (en)
Inventor
Ivaylo Gentschev
Joachim Fensterle
Ulf R Rapp
Werner Goebel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ATERNA ZENTARIS GmbH
Original Assignee
ATERNA ZENTARIS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ATERNA ZENTARIS GmbH filed Critical ATERNA ZENTARIS GmbH
Publication of DE602007006985D1 publication Critical patent/DE602007006985D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
DE602007006985T 2006-11-13 2007-11-13 Mikroorganismen als träger von für antigene und proteintoxine codierende nukleotidsequenzen, verfahren zur herstellung und verwendungen davon Active DE602007006985D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86548406P 2006-11-13 2006-11-13
EP06123974A EP1921149A1 (de) 2006-11-13 2006-11-13 Mikroorganismen als Träger von Nukleotidsequenzen, die für Antigene und Toxine kodieren, Verfahren zur Herstellung und deren Verwendungen
US93914007P 2007-05-21 2007-05-21
PCT/EP2007/062237 WO2008058944A1 (en) 2006-11-13 2007-11-13 Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof

Publications (1)

Publication Number Publication Date
DE602007006985D1 true DE602007006985D1 (de) 2010-07-15

Family

ID=37846081

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007006985T Active DE602007006985D1 (de) 2006-11-13 2007-11-13 Mikroorganismen als träger von für antigene und proteintoxine codierende nukleotidsequenzen, verfahren zur herstellung und verwendungen davon

Country Status (30)

Country Link
US (1) US8669091B2 (de)
EP (2) EP1921149A1 (de)
JP (1) JP5479102B2 (de)
KR (1) KR101505413B1 (de)
CN (1) CN101595219B (de)
AR (1) AR063795A1 (de)
AT (1) ATE469971T1 (de)
AU (1) AU2007321266B2 (de)
BR (1) BRPI0719003A2 (de)
CA (1) CA2669219A1 (de)
CY (1) CY1111035T1 (de)
DE (1) DE602007006985D1 (de)
DK (1) DK2092067T3 (de)
ES (1) ES2347019T3 (de)
HK (1) HK1138314A1 (de)
HR (1) HRP20100466T1 (de)
IL (1) IL198736A0 (de)
ME (1) ME01846B (de)
MX (1) MX2009005038A (de)
NO (1) NO20092278L (de)
NZ (1) NZ576947A (de)
PL (1) PL2092067T3 (de)
PT (1) PT2092067E (de)
RS (1) RS51416B (de)
RU (1) RU2447145C2 (de)
SI (1) SI2092067T1 (de)
TW (1) TWI394834B (de)
UA (1) UA94974C2 (de)
WO (1) WO2008058944A1 (de)
ZA (1) ZA200903022B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2331271B1 (es) * 2007-06-29 2010-10-14 Universidad Del Pais Vasco Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas.
US8877201B2 (en) * 2007-10-25 2014-11-04 Wake Forest University Health Sciences Bordetella outer-membrane protein antigens and methods of making and using the same
US20090208461A1 (en) * 2008-02-05 2009-08-20 Zentaris Gmbh Recombinant bacteria with e.coli hemolysin secretion system and increased expression and/or secretion of hlya, process of manufacturing and uses thereof
US20120020996A1 (en) * 2008-08-06 2012-01-26 Jonathan Lewis Telfer Vaccines against clostridium difficile and methods of use
KR101104077B1 (ko) * 2008-10-14 2012-01-11 건국대학교 산학협력단 Ｅｇｒ－１의 발현을 증가시키는 활성을 갖는 신규한 엔터로박테리아속에 속하는 신규균주 및 그 균주를 포함하는 조성물의 항암제로서의 용도
CN101480489B (zh) * 2008-12-03 2012-07-04 中国人民解放军第三军医大学 疟原虫环子孢子蛋白抗肿瘤增殖和迁移的新用途
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
GB2478734A (en) * 2010-03-15 2011-09-21 Sense Proteomic Ltd Auto-antibody biomarkers of prostate cancer
KR101229596B1 (ko) * 2010-05-13 2013-02-04 한국외국어대학교 연구산학협력단 사람 락토페리신 펩티드의 대장균 발현 플라스미드 및 그 용도
DK2753352T4 (da) 2010-09-03 2022-09-12 Valneva Austria Gmbh Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf
BR112013022331B1 (pt) * 2011-03-02 2021-01-26 Futuragene Israel Ltd. vetor de expressão de ácido nucleico, e, método para gerar uma planta que compreende resistência intensificada a um patógeno bacteriano
CN103687611A (zh) 2011-03-11 2014-03-26 阿德瓦希斯公司 基于李斯特菌属的佐剂
SG11201400432VA (en) * 2011-09-06 2014-08-28 Agency Science Tech & Res Polypeptide vaccine
ES2806605T3 (es) * 2011-09-23 2021-02-18 Univ Loma Linda Cepas bacterianas que expresan genes de metilasa y sus usos
US11680273B2 (en) 2011-09-23 2023-06-20 Loma Linda University Treatment of autoimmune diseases
EP2583975A1 (de) * 2011-10-21 2013-04-24 Heinrich-Heine-Universität Düsseldorf Mittel und Verfahren zur Expression und Sekretion von Peptiden und Proteinen
US9902760B2 (en) * 2011-11-23 2018-02-27 Bioven 3 Limited Recombinant proteins and their therapeutic uses
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment
US9499856B2 (en) 2012-04-02 2016-11-22 The Board Institute, Inc. DDR2 mutations in squamous cell lung cancer
US9409956B2 (en) * 2012-05-23 2016-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Salmonella typhi Ty21a expressing Yersinia pestis F1-V fusion protein and uses thereof
JPWO2014017491A1 (ja) * 2012-07-26 2016-07-11 国立研究開発法人国立がん研究センター Ｃｅｐ５５遺伝子とｒｅｔ遺伝子との融合遺伝子
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
CN111978409B (zh) 2013-03-15 2024-01-26 因斯瑞拜奥有限公司 自组装合成蛋白
EP2792686A1 (de) 2013-04-17 2014-10-22 Heinrich-Heine-Universität Düsseldorf Verfahren zur Expression von Peptiden und Proteinen
MX364922B (es) 2013-04-25 2019-05-14 Vaximm Ag Vacuna de adn que dirige wt-1 novedosa para inmunoterapia contra cáncer.
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
ES2754508T3 (es) * 2014-05-21 2020-04-17 Univ Basel Transporte de proteínas basado en bacterias
US10004751B2 (en) 2014-07-10 2018-06-26 The J. David Gladstone Institutes Compositions and methods for treating Dengue virus infection
US20160030531A1 (en) * 2014-08-01 2016-02-04 Northwestern University Bacterial toxins and uses thereof as ras specific proteases
MA41217A (fr) * 2014-12-19 2017-10-24 Advaxis Inc Polythérapies ayant des souches de listeria recombinées
CN106146508A (zh) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
CA3018308A1 (en) 2015-04-28 2016-11-03 Albert Einstein College Of Medicine, Inc. Treatment of cancer using recall antigens delivered by attenuated bacteria
JP7266834B2 (ja) 2015-12-28 2023-05-01 北海道公立大学法人 札幌医科大学 腫瘍抗原ペプチド
CN105601753A (zh) * 2016-02-22 2016-05-25 潍坊医学院 结核杆菌噬菌体双组份融合溶菌蛋白及其制备方法和应用
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
AU2017332854A1 (en) 2016-09-21 2019-04-11 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
CN107858430B (zh) * 2017-11-20 2019-01-04 武汉迈特维尔生物科技有限公司 一种用于诊断预示Her-2过表达型乳腺癌骨转移的基因诊断试剂盒
CN109593771B (zh) * 2018-07-27 2022-03-29 四川大学华西医院 一种人类map2k5第1100位碱基突变基因及其检测试剂盒
CN109486832B (zh) * 2018-12-29 2021-11-23 中国农业科学院棉花研究所 一种创建有限生长株型棉花的方法
CN110330548B (zh) * 2019-06-28 2021-03-09 哈尔滨医科大学 一种抗肿瘤多肽及其在制备抗肿瘤药物中的应用
CN110237240A (zh) * 2019-07-03 2019-09-17 上海市肺科医院 可溶性受体酪氨酸激酶sAxl在治疗结核病中的应用
WO2021026335A1 (en) * 2019-08-08 2021-02-11 The Trustees Of Indiana University Methods for identifying and treating urinary tract infections
JP2022544393A (ja) 2019-08-12 2022-10-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド マクロファージ刺激１受容体（ｍｓｔ１ｒ）バリアント及びその使用
CN111635937B (zh) * 2020-06-29 2021-10-08 江苏省中医院 Ass1或bckdk抑制剂在制备治疗溃疡性结肠炎的药物中的应用
KR20220063113A (ko) * 2020-11-09 2022-05-17 전남대학교산학협력단 암의 예방 및 치료용 살모넬라 균주 및 이의 용도
WO2022225267A1 (ko) * 2021-04-19 2022-10-27 엠브릭스 주식회사 보툴리늄 독소 전위 도메인 및 엔도라이신을 포함하는 단백질 복합체 및 이를 포함하는 항균 조성물
CN117805372A (zh) * 2021-08-30 2024-04-02 河南中医药大学 一种生物标记物在制备检测桥本甲状腺炎脾肾阳虚证的试剂或试剂盒中的应用
CN114921546B (zh) * 2022-05-13 2023-02-21 核工业总医院 circHIPK2作为乳腺癌生物标志物的应用
GB202209115D0 (en) * 2022-06-21 2022-08-10 Chain Biotechnology Ltd Compositions and methods
WO2024054673A1 (en) * 2022-09-09 2024-03-14 Texas Tech University System Listeria monocytogenes as a vector for tumor-specific delivery of chemotherapeutic agents
CN115976033B (zh) * 2022-12-14 2024-05-17 西南大学 瓜实蝇tssk1和tssk3基因及其应用
CN116875520A (zh) * 2023-07-12 2023-10-13 吉林农业大学 表达核糖体失活蛋白的乳酸菌及其在抗轮状病毒中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02170053A (ja) * 1988-12-23 1990-06-29 Meiji Seika Kaisha Ltd 微生物の検出方法及び装置
RU2092556C1 (ru) * 1995-08-29 1997-10-10 Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации Способ введения чужеродных генов в геномы грамотрицательных микроорганизмов, плазмидный вектор ркс47м для введения чужеродных генов в геномы грамотрицательных микроорганизмов, способ конструирования плазмидного вектора ркс47м
WO1998006428A1 (en) * 1996-08-16 1998-02-19 The Uab Research Foundation Mucosal immunogens for novel vaccines
US6036953A (en) * 1996-11-29 2000-03-14 The General Hospital Corporation Heterologous antigens in live cell V. cholerae strains
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
CN1411512A (zh) * 1999-10-20 2003-04-16 约翰霍普金斯大学医学院 嵌合的免疫原性组合物及其编码核酸
GB0030067D0 (en) * 2000-12-11 2001-01-24 Univ Bristol Therapeutic agent
RU2216590C1 (ru) * 2002-02-26 2003-11-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Рекомбинантный аттенуированный штамм бактерий salmonella typhimurium t10/pkhbc - продуцент корового антигена вируса гепатита в
DE10208653A1 (de) 2002-02-28 2003-09-18 Medinnova Ges Med Innovationen Mikroorganismus als Träger von Nukleotidsequenzen kodierend für Zellantigene zur Behandlung von Tumoren

Also Published As

Publication number Publication date
CN101595219A (zh) 2009-12-02
AU2007321266A1 (en) 2008-05-22
US8669091B2 (en) 2014-03-11
WO2008058944A1 (en) 2008-05-22
JP5479102B2 (ja) 2014-04-23
US20110287037A1 (en) 2011-11-24
PL2092067T3 (pl) 2010-11-30
ATE469971T1 (de) 2010-06-15
NO20092278L (no) 2009-08-13
KR101505413B1 (ko) 2015-03-25
SI2092067T1 (sl) 2010-10-29
HRP20100466T1 (hr) 2010-10-31
BRPI0719003A2 (pt) 2013-12-17
RU2009122560A (ru) 2010-12-20
IL198736A0 (en) 2011-08-01
UA94974C2 (uk) 2011-06-25
HK1138314A1 (zh) 2010-08-20
RU2447145C2 (ru) 2012-04-10
JP2010508861A (ja) 2010-03-25
ME01846B (me) 2011-02-28
AU2007321266B2 (en) 2012-11-15
CY1111035T1 (el) 2015-06-11
KR20090092803A (ko) 2009-09-01
AR063795A1 (es) 2009-02-18
TW200837193A (en) 2008-09-16
CN101595219B (zh) 2016-01-27
MX2009005038A (es) 2009-05-25
ES2347019T3 (es) 2010-10-22
CA2669219A1 (en) 2008-05-22
TWI394834B (zh) 2013-05-01
RS51416B (en) 2011-02-28
EP1921149A1 (de) 2008-05-14
NZ576947A (en) 2011-12-22
DK2092067T3 (da) 2010-09-06
EP2092067B1 (de) 2010-06-02
EP2092067A1 (de) 2009-08-26
ZA200903022B (en) 2010-03-31
PT2092067E (pt) 2010-08-31

Similar Documents

Publication Publication Date Title
DE602007006985D1 (de) Mikroorganismen als träger von für antigene und proteintoxine codierende nukleotidsequenzen, verfahren zur herstellung und verwendungen davon
DE502006007528D1 (de) Verfahren zur kontinuierlichen Herstellung von Kohlenstofffasern
DE502006000218D1 (de) Verfahren zur Herstellung von SiOC-verknüpften, linearen Polydialkylsiloxan-Polyoxyalkylen-Blockcopolymeren
IL172297A0 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis iii
EP1924683A4 (de) Verfahren zur behandlung von methanemissionen
HK1243460A1 (zh) 產生單一序列dna探針的方法和組合物、dna探針的標記和這些探針的用途
WO2004087878A3 (en) Novel plant promoters for use in early seed development
ATE447593T1 (de) Niedrigviskose uretdiongruppenhaltige polyadditionsverbindungen, verfahren zur herstellung und verwendung
ATE451425T1 (de) Selbsthaftende additionsvernetzende siliconkautschukmischungen, ein verfahren zu deren herstellung, verfahren zur herstellung von verbund-formteilen und deren verwendung
DE502006000932D1 (de) Verfahren zur Herstellung von Organylhydrogensilanen
DE102009037293A8 (de) Verbesserter Werkstückträger, Verfahren zu seiner Herstellung und dessen Verwendung
DE602008000176D1 (de) Verfahren zur Umwandlung von Glukose in Aniline durch Mikroorganismen
DE502008000313D1 (de) Verfahren zur kontinuierlichen Herstellung von Aminoalkylgruppen aufweisenden Organopolysiloxanen
EP1973945A4 (de) Neue nukleotid- und aminosäuresequenzen und verfahren zu deren anwendung in der diagnose
DE602006012325D1 (de) Verfahren zur Herstellung von sphärischen Trägern für Polymerisationsatalystoren von Olefinen
ZA200805224B (en) Geopolymeric particles, fibers, shaped articles and methods of manufacture
DE502008000793D1 (de) Mehrstufiges Verfahren zur Herstellung von Aminoalkylgruppen aufweisenden Organopolysiloxanen
DE502005007702D1 (de) Verfahren zur herstellung von terrylen-3,4:11,12-t
ATE437984T1 (de) Textiles flächengebilde, verfahren zur herstellung und verwendung
EP2116598A4 (de) Neuartige beta-galactosid-alpha-2,6-sialyltransferase, gen zu deren kodierung und verfahren zur erhöhung der enzymatischen aktivität
DE502006000023D1 (de) Verfahren zur Herstellung von Silanolgruppen aufweisenden Organopolysiloxanen
DE502005000184D1 (de) Verfahren zur Herstellung von linearen Si-H-Gruppen aufweisenden Organopolysiloxanen
DE502006002029D1 (de) Verfahren zur herstellung von polyetheraminen
EP1954826A4 (de) Neue nukleotid- und aminosäuresequenzen sowie tests und verfahren für deren verwendung zur diagnose
GB0514502D0 (en) Substituted organopolysiloxanes containing phosphonic groups,method for the production and use thereof